In vitro activity of triclosan ( TCN ) and thiolactomycin ( TLM ) against multi-drug-resistant ( MDR ) strains of mycobacterium tuberculosis ( M. tb ) Source: Eur Respir J 2004; 24: Suppl. 48, 722s Year: 2004
Minimal inhibitory concentrations (MIC) of first line drugs in multidrug resistant strains of M. tuberculosis (MDR-TB) Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010
Amikacin (AMK) minimum inhibitory concentrations (MICs) and mutational resistance in patients with treatment-refractory nontuberculous mycobacteria (NTM) lung disease (LD) treated with liposomal amikacin for inhalation (LAI) Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook Year: 2015
Drug resistance of Mycobacterium tuberculosis to fluoroquinolones (Q) Source: Eur Respir J 2003; 22: Suppl. 45, 41s Year: 2003
Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Primary multidrug resistance (PMDR) of mycobacterium tuberculosis (MBT) to antimycobacterial drugs (AMBTD) in the patients with destructive TB. Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008
Bio-Chip (BCh) technology for diagnostics of multidrug resistance (DR) of mycobacterium tuberculosis (MBT) from patients with disseminated tuberculosis (DT) Source: Annual Congress 2008 - Genetics, immunology and microbiology of tuberculosis Year: 2008
Treatment outcomes of tuberculosis (TB) patients with rifampin (RMP) or RMP and isoniazid (INH) resistance receiving standard regimen Source: Eur Respir J 2003; 22: Suppl. 45, 42s Year: 2003
Primary resistance (PR) of mycobacterium tuberculosis (MBT) to antimicrobial drugs (AMBD) in patients (P) with destructive pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 655s Year: 2004
Susceptibility of mycobacterium avium complex and mycobacterium xenopi to rifampin, rifapentine, clarithromycin and moxifloxacin, alone or in combination with ethambutol Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB) : global response Source: International Congress 2017 – Update on TB: latest news Year: 2017
Comparative analysis between multidrug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB) in HIV(+) patients Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009
Express diagnostics of mycobacterium tuberculosis (MBT) drug resistance at disseminated tuberculosis (DT) Source: Annual Congress 2008 - Diagnosis of tuberculosis: problems and perspectives Year: 2008
Drug resistance patterns in patients with multi-drug resistant tuberculosis (MDR – TB) Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: diagnostic tools Year: 2012
Efficacy and tolerability of linezolid in multidrug-resistant tuberculosis (MDR/XDR-TB) Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008
Safety and efficacy of linezolid, clarithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 587s Year: 2006
In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis Source: Eur Respir J 2014; 44: 808-811 Year: 2014
MIC and gyrA/B genetic analyses of fluoroquinolones against mycobacterium tuberculosis isolated in Japan Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Rapid molecular detection of rifampicin and isoniazid resistance and identification of mutations in resistant genes of multi-drug resistant tuberculosis (MDR-TB) patients Source: Annual Congress 2011 - Novel strategies for the diagnosis of tuberculosis Year: 2011
Treatment by linezolid of lung TB caused by drug resistant mycobacterium (MBT) Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016